Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx NV

Division of Sanofi
www.ablynx.com

Latest From Ablynx NV

Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.

Business Strategies Deals

Galapagos CEO Interview: Independence Allows Us To Keep Innovating

Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."

Deals Companies

The Challenges Facing Paul Hudson At the Helm of Sanofi

Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.

Leadership Strategy

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Edwin Moses, PhD, CEO
    Wim Ottevaere, CFO
    Markus Ewert, PhD, CBO
    Robert K Zeldin, MD, CMO
    Heylen Johan, Chief Commerical Officer
    Robert Friesen, PhD, CSO
  • Contact Info
  • Ablynx NV
    Phone: (32) 9 262 00 00
    Technologiepark 21
    Ghent/Zwijnaarde, 9052
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register